Clik here to view.
GSK’s COPD drug Relovair targeted for mid-2012 drug filings
GlaxoSmithKline (NYSE:GSK) plans to submit new drug applications in the United States and Europe this year for Relovair, an inhaled drug candidate developed to treat asthma and chronic obstructive...
View ArticleClik here to view.
GSK’s Dingemans discusses Relovair, strategy for succeeding Advair
Simon Dingemans GlaxoSmithKline (NYSE:GSK) CFO Simon Dingemans is among those at the JP Morgan Global Healthcare Conference this week in San Francisco and he took some time out to discuss respiratory...
View ArticleClik here to view.
Regenerative medicine for lung disease focus of $2.5 million Penn grant
A study exploring lung repair and tissue regeneration to fight lung diseases by a team at the Perelman School of Medicine at the University of Pennsylvania in Philadelphia has received a $2.5 million...
View ArticleClik here to view.
Merck’s Canadian arm loses Supreme Court of Canada case over trade secrets
The Supreme Court of Canada has ruled against Merck’s (NYSE:MRK) Canadian division in a case focused on the question of what are corporate trade secrets in the drug approval process, according to...
View ArticleClik here to view.
Depression remains TRGT’s lead target, but CEO touts other shots on goal
Depression treatment TC-5214 remains Targacept‘s (NASDAQ:TRGT) lead drug candidate and perhaps it was with that in mind that CEO Don DeBethizy started the earnings conference call with an update on...
View ArticleClik here to view.
Breath sensor company develops cost-effective lung function test
An early stage pulmonary medical device company has developed a breath sensor to measure air speed, which helps diagnose lung disease. The company’s device offers a more cost-effective option to the...
View ArticleClik here to view.
GSK’s Relovair on track for COPD drug filing; talks on asthma in U.S. ongoing
GlaxoSmithKline’s (NYSE:GSK) Relovair, a respiratory drug candidate, will have drug applications filed in Europe and the United States this year despite mixed trial results comparing the compound to...
View ArticleClik here to view.
Asthma drug shows promise, diabetes study fails in Targacept phase 2 trials
A Targacept (NASDAQ:TRGT) compound developed for potential applications in asthma and type 2 diabetes has mixed mid-stage clinical trial results that show success in asthma but failure in diabetes. As...
View ArticleClik here to view.
GSK invests $212M in Relovair partner Theravance
GlaxoSmithKline (NYSE:GSK) is pumping $212.8 million into drug partner Theravance (NASDAQ:THRX) as the companies move ahead with plans for regulatory submissions for respiratory treatment Relovair....
View ArticleClik here to view.
Asthma compound hits just one of two phase 2 goals, TRGT reanalysis shows
The asthma treatment Targacept (NASDAQ:TRGT) is developing actually did not perform as well in clinical trials as initially thought. Targacept last month released top-line phase 2 results for TC-6987...
View ArticleClik here to view.
GSK, FivePrime partner to discover new asthma and COPD treatments
GlaxoSmithKline (NYSE:GSK) is partnering with California biotechnology company Five Prime Therapeutics to discover new treatments for respiratory disorders. It’s the second drug discovery alliance in...
View ArticleClik here to view.
Targacept’s drug pipeline must fill gap left by lead drug’s phase 3 failure
Targacept‘s (NASDAQ:TRGT) first quarter dealt the company several blows with a phase 3 clinical trial failure for its lead drug candidate and a missed target in another clinical program. Failure of...
View ArticleClik here to view.
Biopharma raising $500K eyes competitive asthma/COPD drug market
A biopharmaceutical startup developing a new treatment for asthma that targets the nitric oxide signaling system has raised $50,000 of a planned $500,000 fundraise, according to recently filed U.S....
View ArticleClik here to view.
Biopharma led by transplant expert raising up to $3M for severe asthma/COPD...
Company name: Apellis Pharmaceuticals Inc. Industry: Pharmaceuticals. Location: Crestwood, Kentucky. Solution/product: To address chronic inflammatory diseases, starting with severe asthma and chronic...
View ArticleClik here to view.
Inhaling steroids stunts growth, but not much
CHICAGO (Reuters) - Adults who took inhaled steroids as children to control their asthma may be shorter than they otherwise would have been, but only by a little, U.S. researchers said on Monday....
View ArticleClik here to view.
Novartis racing GSK to develop steroid-free lung disease drugs and new...
LONDON, Sept 4 (Reuters) - Swiss group Novartis (NYSE: NVS) has stepped up its challenge to GlaxoSmithKline's (NYSE: GSK) traditional domination of the lung drug market, stealing the limelight with...
View ArticleClik here to view.
A mom-inspired device could let kids with asthma take their daily meds while...
Frustrated by the challenges of giving her young son his daily asthma treatments, Sarah Cota came up with an idea. Why not ease the burden of using a nebulizer by taking away the mask and using it...
View ArticleClik here to view.
Fresno seeks to cut city’s 20% asthma rate via social-impact bond that pays...
NEW YORK (Reuters) - The city of Fresno, Calif., will be the first municipality in the United States to see whether "social impact bonds," an innovative security that promotes a societal benefit, can...
View ArticleClik here to view.
School “hand hygiene” plan shows no impact on rate of asthma attacks
NEW YORK (Reuters Health) - An arsenal of hand sanitizers, hygiene education and good old-fashioned soap failed to prevent asthma attacks among school children in one Alabama county. For children with...
View ArticleClik here to view.
Study: Many women stop asthma meds while pregnant
NEW YORK (Reuters Health) - Almost a third of women on asthma control medications stop using them during the first few months of pregnancy - despite advice that a mother's uncontrolled asthma is more...
View Article
